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Abstract A 70-year-old man with metastatic renal cell
carcinoma developed progressive liver metastases after
8 weeks of treatment with the multitargeted tyrosine kinase
inhibitor (TKI) sunitinib. He then participated in the phase
III placebo-controlled clinical trial of the oral mammalian
target of rapamycin (mTOR) inhibitor everolimus, initially
randomized to placebo (but had disease progression after
3 months) and crossed over to everolimus at time of
unblinding. The patient had stable disease after 8 weeks
(two cycles) of everolimus that was maintained until
28 months of therapy, at which time the patient had
achieved a partial response. This case illustrates the
potential for patients with metastatic renal cell carcinoma,
a malignancy with historically poor prognosis, to derive
long-term beneﬁt from everolimus when used in a manner
consistent with its approved indication (after TKI therapy
with sunitinib or sorafenib).
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Introduction
Patients with metastatic renal cell carcinoma (mRCC) have
historically had a universally poor prognosis given the
inability of systemic chemotherapy and immunotherapy to
alter the natural history of the disease in most cases.
In recent years, there have been a series of phase III
randomized trials showing beneﬁt for targeted drugs,
namely the small-molecule multitargeted tyrosine kinase
inhibitors (TKIs) sorafenib [1], sunitinib [2], and pazopanib
[3] and the mammalian target of rapamycin (mTOR)
inhibitors temsirolimus [4] and everolimus [5]. The oral
mTOR inhibitor everolimus demonstrated a signiﬁcant
improvement in progression-free survival (PFS) versus
placebo in the phase III RECORD-1 (REnal Cell cancer
treatment with Oral RAD001 given Daily) trial (clinical-
trials.gov identiﬁer NCT00410124), in which clear-cell
mRCC patients progressing within 6 months of discon-
tinuing sorafenib and/or sunitinib were randomized to
receive best supportive care in conjunction with everolimus
10 mg/day or placebo [5]. Per disease status assessment by
independent central review, median PFS was 4.9 months
with everolimus versus 1.9 months with placebo, translat-
ing into a 67% (P\0.0001) reduction in the risk of pro-
gression or death. Stable disease was documented in 67%
of everolimus recipients (with a 2% partial response rate)
versus 32% of placebo recipients [5, 6].
Herein, we describe a case of a sunitinib-pretreated
participant in RECORD-1 with prolonged stable disease,
who went on to achieve a partial response after 28 months
of therapy.
Case report
A 70-year-old man with a medical history signiﬁcant for
hypertension, hypercholesterolemia, and rheumatoid arthri-
tis presented to Memorial Sloan-Kettering Cancer Center
(MSKCC) for the medical management of recently diag-
nosed mRCC. He had undergone a left radical nephrectomy
for a T3 N0 M0 clear-cell RCC. After a 3-year disease-free
interval, he had developed recurrent disease in the lungs.
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both showing clear-cell histology. After a 1-year disease-
free interval, he developed recurrent disease in the liver. He
received sunitinib but had progressive liver metastases after
8 weeks of treatment.
The patient was enrolled into the RECORD-1 random-
ized phase III trial of everolimus versus placebo in con-
junction with best supportive care (clinicaltrials.gov
identiﬁer NCT00410124) under informed consent. Baseline
characteristics included a Karnofsky Performance Status of
90% and a favorable MSKCC risk group. He progressed
after three cycles of therapy, each of which was deﬁned as
28 days of treatment. Unblinding revealed that the patient
was receiving placebo and, as permitted per the protocol,
he crossed over to receive oral everolimus 10 mg daily.
Response was assessed with CT scans at the initial
screening and repeated every 8 weeks for the ﬁrst 2 years
and every 12 weeks for the remainder of the study. Using
RECIST to classify treatment responses, the patient
achieved stable disease after 8 weeks (two cycles) of
treatment. Stable disease persisted until cycle 28 when he
achieved a partial response (Figs. 1 and 2), with regression
in liver metastases. Partial response persisted for 9 months,
at which time treatment was discontinued due to grade 3
transaminitis that was likely secondary to alcohol con-
sumption. No grade 3 or 4 toxicities occurred previously
over the course of treatment. He resumed off-protocol
everolimus after the cessation of alcohol use and resultant
resolution of the transaminitis and remains on treatment as
of the time of this writing. To date, the patient has received
32 months of treatment on the clinical trial plus 8 months
of off-protocol treatment for a total of 40 months of
everolimus treatment.
Toxicities during the early course of treatment included
grade 1 rash, fatigue, stomatitis, and ankle swelling.
The most notable toxicity later in the course of treatment
(after 18 months) was grade 2 hypertriglyceridemia. This
led to an increase in the patient’s statin drug dose.
Discussion
The past decade marked a rapidly evolving era for the
treatment of mRCC given the documented beneﬁt of oral
targeted therapy with the multitargeted TKIs sunitinib and
sorafenib for this highly chemotherapy-resistant, poor-
prognosis malignancy. Immunotherapy has served an
important role, despite conferring limited beneﬁt and gen-
erally high toxicity. Patients requiring discontinuation of
these agents because of disease progression or treatment-
relatedtoxicityquicklysurfacedasanewpopulationwithan
unmet medical need. Based on the RECORD-1 experience
[5], everolimus was granted U.S. Food and Drug Adminis-
tration approval for the treatment of mRCC after failure of
prior sunitinib and/or sorafenib. Everolimus has since been
incorporated into clinical practice guidelines (e.g., National
Comprehensive Cancer Network [7], European Organiza-
tion for Research and Treatment of Cancer [8]), providing a
muchneededtherapeuticoptionforuseincommunity-based
practice.
A recently presented sub-analysis of RECORD-1
focused on participants aged C70 years demonstrated that
the prolonged PFS beneﬁt and tolerability of everolimus
are maintained in elderly patients, despite some adverse
events occurring more frequently than in the overall pop-
ulation [9]. The elderly patient described here, with two
separate episodes of recurrent clear-cell RCC and pro-
gressive disease on sunitinib and while on the placebo arm
of the RECORD-1 trial, converted from stable disease to a
partial response after nearly 3 years of everolimus therapy.
Although most of the clinical beneﬁt of everolimus is in the
Fig. 1 Baseline scan shows large heterogenous hepatic mass and a
smaller enhancing mass (arrows)
Fig. 2 Scan shows decrease in size and necrosis of hepatic masses on
the follow-up study 30 months later (arrows)
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were seen among everolimus recipients in RECORD-1
[5, 6] and the prior phase II clinical trial in mRCC [10].
These ﬁndings are consistent with that from a retrospective
review of patients with intermediate or poor-prognosis
mRCC treated with temsirolimus after failure of a VEGF-
targeted therapy in a compassionate-use program. The
majority of patients achieved stable disease; comparatively
few patients achieved a partial response [11].
The patient described here tolerated everolimus therapy
well, as illustrated by his long-term use. Although treatment
was discontinued during the clinical trial because of trans-
aminitis, this event was considered to be related to the
patient’s alcohol consumption and has not recurred since
reinstitution of everolimus. Transaminase elevations were
reported more frequently with everolimus versus placebo in
RECORD-1, with raised aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) in 21 and 18% of
everolimus recipients, respectively (7 and 4%, respectively,
with placebo), which were limited to grade 1/2 severity
except for grade 3 AST and ALT elevations in 1 patient
each [5]. In RECORD-1, hypercholesterolemia was the
second most common laboratory abnormality (after ane-
mia), reported in 76% of everolimus recipients (including
3% grade 3 incidence) versus 32% of placebo recipients.
Stomatitis, rash, fatigue, and asthenia were the most com-
mon adverse events reported during everolimus therapy in
RECORD-1, with grade 3/4 incidences\5% for these and
other treatment-related adverse events (primarily gastroin-
testinal issues).
This example of everolimus-associated prolonged dis-
ease stabilization (and subsequent partial response) in a
sunitinib-pretreated patient represents the successful
application of approved targeted agents in this setting.
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